Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.
Ovarian, Fallopian Tube & Primary Peritoneal Cancer — 342 Curated Clinical Trials
| NCT Identifier | Title & Sponsor | Phase / Status |
|---|---|---|
| NCT00539162 | Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women | NA RECRUITING |
| NCT01174121 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | PHASE2 RECRUITING |
| NCT01558544 | Cryopreservation of Ovarian Tissue | NA RECRUITING |
| NCT02830724 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | PHASE1|PHASE2 RECRUITING |
| NCT03011684 | Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial | PHASE3 RECRUITING |
| NCT03067181 | Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | PHASE3 RECRUITING |
| NCT03412877 | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | PHASE2 RECRUITING |
| NCT03544983 | Genetic Education in BRCA Families | NA ENROLLING_BY_INVITATION |
| NCT03564340 | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | PHASE1|PHASE2 RECRUITING |
| NCT03604315 | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF | PHASE1 RECRUITING |
| NCT03686124 | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT03854110 | A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine | PHASE1 RECRUITING |
| NCT03878849 | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer | PHASE2 RECRUITING |
| NCT03968406 | Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | PHASE1 RECRUITING |
| NCT04038619 | Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | PHASE1 RECRUITING |
| NCT04055649 | ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer | PHASE2 RECRUITING |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | PHASE1|PHASE2 RECRUITING |
| NCT04107077 | Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer | PHASE2 RECRUITING |
| NCT04196257 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | PHASE1 RECRUITING |
| NCT04251052 | A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | NA RECRUITING |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | PHASE1 RECRUITING |
| NCT04294927 | TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention | NA RECRUITING |
| NCT04300556 | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | PHASE1|PHASE2 RECRUITING |
| NCT04329494 | PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer | PHASE1 RECRUITING |
| NCT04389632 | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT04429542 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT04469764 | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | PHASE2 RECRUITING |
| NCT04473833 | Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer | NA RECRUITING |
| NCT04494945 | Identifying and Caring for Individuals With Inherited Cancer Syndrome | NA RECRUITING |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | PHASE1|PHASE2 RECRUITING |
| NCT04516447 | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer | PHASE1 RECRUITING |
| NCT04520139 | Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT | PHASE1|PHASE2 RECRUITING |
| NCT04575935 | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | PHASE3 RECRUITING |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | PHASE1|PHASE2 RECRUITING |
| NCT04585958 | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer | PHASE1 RECRUITING |
| NCT04590326 | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab | PHASE1|PHASE2 RECRUITING |
| NCT04606914 | Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer | PHASE2 RECRUITING |
| NCT04633239 | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | PHASE1 RECRUITING |
| NCT04641247 | A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | PHASE2 RECRUITING |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT04701645 | Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer | PHASE1 RECRUITING |
| NCT04751435 | Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients | NA RECRUITING |
| NCT04752826 | BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | PHASE1|PHASE2 RECRUITING |
| NCT04779554 | Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC | PHASE2 RECRUITING |
| NCT04804007 | Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT | PHASE2 RECRUITING |
| NCT04847063 | Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies | PHASE1 RECRUITING |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT04858009 | Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis | PHASE2 ACTIVE_NOT_RECRUITING |
| NCT04890613 | Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | PHASE1 RECRUITING |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT04907643 | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | NA RECRUITING |
| NCT04918186 | Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer | PHASE2 RECRUITING |
| NCT04919629 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | PHASE2 RECRUITING |
| NCT04997096 | Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy | NA RECRUITING |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | PHASE1|PHASE2 RECRUITING |
| NCT05005403 | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan | PHASE1 RECRUITING |
| NCT05039801 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT05071937 | ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer | PHASE2 RECRUITING |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study | PHASE1|PHASE2 RECRUITING |
| NCT05092373 | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | PHASE1 RECRUITING |
| NCT05103683 | First in Human Study of TORL-1-23 in Participants With Advanced Cancer | PHASE1 RECRUITING |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | PHASE1 RECRUITING |
| NCT05112601 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | PHASE2 RECRUITING |
| NCT05113368 | Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer | PHASE2 RECRUITING |
| NCT05123482 | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | PHASE1|PHASE2 RECRUITING |
| NCT05123807 | Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) | PHASE2 RECRUITING |
| NCT05128825 | A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | PHASE2 RECRUITING |
| NCT05130606 | CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing | NA RECRUITING |
| NCT05225363 | Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer | PHASE1 RECRUITING |
| NCT05225428 | Video Education With Result Dependent dIsclosure | NA COMPLETED |
| NCT05227326 | AOH1996 for the Treatment of Refractory Solid Tumors | PHASE1 RECRUITING |
| NCT05231122 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | PHASE2 RECRUITING |
| NCT05281471 | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | PHASE3 RECRUITING |
| NCT05287451 | Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study | NA RECRUITING |
| NCT05297734 | Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer | NA RECRUITING |
| NCT05316129 | Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer | PHASE1 RECRUITING |
| NCT05349227 | Comprehensive Outcomes for After Cancer Health | NA RECRUITING |
| NCT05377996 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT05417594 | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | PHASE1|PHASE2 RECRUITING |
| NCT05429970 | A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) | NA RECRUITING |
| NCT05467891 | Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | PHASE2 RECRUITING |
| NCT05479045 | A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients | PHASE2 WITHDRAWN |
| NCT05489211 | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | PHASE2 RECRUITING |
| NCT05503797 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | PHASE2 RECRUITING |
| NCT05512208 | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | PHASE2 RECRUITING |
| NCT05538091 | Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | PHASE2 RECRUITING |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | PHASE2 RECRUITING |
| NCT05568680 | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | PHASE1 RECRUITING |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | PHASE1|PHASE2 RECRUITING |
| NCT05610735 | Combination Therapy for Recurrent Ovarian Cancer | PHASE1|PHASE2 RECRUITING |
| NCT05636111 | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | PHASE1 RECRUITING |
| NCT05645536 | Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study | PHASE3 ENROLLING_BY_INVITATION |
| NCT05649072 | Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics. | NA RECRUITING |
| NCT05659381 | Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer | PHASE3 RECRUITING |
| NCT05684965 | XTX301 in Patients With Advanced Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT05721976 | With Love, Grandma ("Con Cariño, Abuelita") Pilot Study | NA RECRUITING |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | PHASE2 RECRUITING |
| NCT05735080 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer | PHASE1|PHASE2 RECRUITING |
| NCT05739981 | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | PHASE1|PHASE2 RECRUITING |
| NCT05743517 | Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) | NA ACTIVE_NOT_RECRUITING |
| NCT05746897 | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT05752448 | Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O) | NA RECRUITING |
| NCT05753306 | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | PHASE2 RECRUITING |
| NCT05761561 | Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer | NA RECRUITING |
| NCT05768139 | First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT05794659 | Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer | PHASE2 NOT_YET_RECRUITING |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT05804370 | Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) | PHASE3 RECRUITING |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | PHASE1|PHASE2 RECRUITING |
| NCT05844865 | Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis | NA RECRUITING |
| NCT05867251 | Study of AVZO-021 in Patients With Advanced Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT05877599 | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | PHASE1 RECRUITING |
| NCT05879926 | Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | PHASE3 RECRUITING |
| NCT05887609 | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib | PHASE2 RECRUITING |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | PHASE1|PHASE2 RECRUITING |
| NCT05910294 | A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer | NA RECRUITING |
| NCT05914116 | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT05921149 | Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer | NA NOT_YET_RECRUITING |
| NCT05932862 | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT05941507 | A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT05942300 | CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer | PHASE1 RECRUITING |
| NCT05950464 | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | PHASE1 RECRUITING |
| NCT05952453 | Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro | PHASE2 RECRUITING |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | PHASE2 RECRUITING |
| NCT05983276 | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | PHASE2 RECRUITING |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | PHASE1 RECRUITING |
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT05990426 | Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy | NA RECRUITING |
| NCT05998135 | Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer | PHASE2 RECRUITING |
| NCT06014502 | Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06036810 | Spanish Decision Tool for Ovarian Cancer Maintenance Therapy | NA RECRUITING |
| NCT06040970 | Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer | PHASE1|PHASE2 RECRUITING |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression | PHASE1|PHASE2 RECRUITING |
| NCT06065462 | Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 | PHASE1|PHASE2 RECRUITING |
| NCT06072781 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | PHASE3 RECRUITING |
| NCT06083844 | Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy | PHASE2 RECRUITING |
| NCT06084481 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | PHASE1 RECRUITING |
| NCT06084780 | Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) | PHASE2 NOT_YET_RECRUITING |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT06161025 | A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | PHASE2|PHASE3 RECRUITING |
| NCT06172478 | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | PHASE2 RECRUITING |
| NCT06178614 | A Study of JNJ-87890387 for Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06188520 | A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT06220864 | SNV1521 in Participants With Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06234423 | A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06253130 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT06268665 | Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy | PHASE2 RECRUITING |
| NCT06270706 | A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | PHASE1 RECRUITING |
| NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06290193 | Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery | PHASE2 RECRUITING |
| NCT06293898 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | PHASE1 RECRUITING |
| NCT06297525 | Study of STP938 (Dencatistat) in Advanced Solid Tumours | PHASE1 RECRUITING |
| NCT06303505 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC | PHASE1|PHASE2 RECRUITING |
| NCT06305299 | Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | PHASE1 RECRUITING |
| NCT06312124 | A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer | NA RECRUITING |
| NCT06321484 | Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer | PHASE1 RECRUITING |
| NCT06330064 | A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) | PHASE1|PHASE2 RECRUITING |
| NCT06366490 | Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer | PHASE1 RECRUITING |
| NCT06386146 | JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | PHASE1|PHASE2 RECRUITING |
| NCT06386887 | Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer | NA RECRUITING |
| NCT06394804 | A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | PHASE2 RECRUITING |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | PHASE1|PHASE2 RECRUITING |
| NCT06400472 | A Study of Sofe-M in Participants With Selected Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06412120 | Study Evaluating Safety, Tolerability, and Metabolism of Niraparib | PHASE4 RECRUITING |
| NCT06422455 | Access to Genetic Testing in Underserved Patients With Cancer | NA RECRUITING |
| NCT06430541 | Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence | PHASE1 RECRUITING |
| NCT06431594 | A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) | PHASE1 RECRUITING |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06458712 | Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies | PHASE1 RECRUITING |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | PHASE1 RECRUITING |
| NCT06469281 | A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers | PHASE1 RECRUITING |
| NCT06476808 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. | PHASE1 RECRUITING |
| NCT06483048 | MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer | PHASE1 RECRUITING |
| NCT06492070 | Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers | PHASE2 RECRUITING |
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | PHASE2 RECRUITING |
| NCT06504147 | A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery | PHASE2 RECRUITING |
| NCT06511037 | PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis | EARLY_PHASE1 RECRUITING |
| NCT06513962 | Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | PHASE3 RECRUITING |
| NCT06515613 | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06518746 | Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation | NA RECRUITING |
| NCT06526819 | SMP-3124LP in Adults With Advanced Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT06543537 | Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer | NA RECRUITING |
| NCT06545604 | Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer | NA RECRUITING |
| NCT06545942 | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | PHASE1 RECRUITING |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | PHASE2 RECRUITING |
| NCT06580314 | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | PHASE3 RECRUITING |
| NCT06582017 | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | PHASE1 RECRUITING |
| NCT06586957 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | PHASE1 RECRUITING |
| NCT06617923 | Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer | PHASE2 RECRUITING |
| NCT06620029 | BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | PHASE1|PHASE2 NOT_YET_RECRUITING |
| NCT06623396 | A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer | PHASE1 RECRUITING |
| NCT06639074 | Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial | PHASE2 RECRUITING |
| NCT06646627 | Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors | PHASE1 RECRUITING |
| NCT06677190 | Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin | PHASE2 RECRUITING |
| NCT06682988 | A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine | PHASE2 RECRUITING |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | PHASE2 RECRUITING |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | PHASE2 RECRUITING |
| NCT06710288 | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer | PHASE2 RECRUITING |
| NCT06710548 | REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors | NA RECRUITING |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT06730347 | A Study of Lorigerlimab in Participants With Advanced Solid Tumors | PHASE2 RECRUITING |
| NCT06748872 | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma | PHASE1 NOT_YET_RECRUITING |
| NCT06751329 | A Study of DM002 in Patients With Advanced Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT06756035 | CT-95 in Advanced Cancers Associated With Mesothelin Expression | PHASE1 RECRUITING |
| NCT06760507 | Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics | NA RECRUITING |
| NCT06760819 | A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | PHASE2 RECRUITING |
| NCT06774963 | A Phase 1 Study of LNCB74 in Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | PHASE1 RECRUITING |
| NCT06787612 | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | PHASE2 RECRUITING |
| NCT06792552 | A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06796907 | A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | PHASE1|PHASE2 RECRUITING |
| NCT06799065 | First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | PHASE1|PHASE2 RECRUITING |
| NCT06815497 | Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer | PHASE2 RECRUITING |
| NCT06819007 | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | PHASE3 RECRUITING |
| NCT06824467 | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | PHASE3 RECRUITING |
| NCT06840886 | A Study of PHST001 in Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06843447 | A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) | PHASE1|PHASE2 RECRUITING |
| NCT06855706 | An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study | NA RECRUITING |
| NCT06856499 | Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer | PHASE1 RECRUITING |
| NCT06885697 | Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | PHASE1 RECRUITING |
| NCT06887673 | Lipid Mediators & Cancer: Montelukast, SPM, and Almonds | EARLY_PHASE1 NOT_YET_RECRUITING |
| NCT06888921 | A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer | PHASE1|PHASE2 ACTIVE_NOT_RECRUITING |
| NCT06890338 | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | PHASE2 RECRUITING |
| NCT06892275 | The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI | NA RECRUITING |
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | PHASE2 RECRUITING |
| NCT06907043 | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. | PHASE1|PHASE2 RECRUITING |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06914726 | Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes | NA ENROLLING_BY_INVITATION |
| NCT06915025 | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer | PHASE3 RECRUITING |
| NCT06930755 | Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer | PHASE1 RECRUITING |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT06953089 | DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | PHASE2 RECRUITING |
| NCT06964009 | DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer | PHASE1 RECRUITING |
| NCT06971744 | Autophagy Maintenance (AUTOMAIN) | PHASE2 RECRUITING |
| NCT06979596 | A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | PHASE2 RECRUITING |
| NCT06993844 | Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT06995898 | The Vanguard Study: Testing a New Way to Screen for Cancer | NA RECRUITING |
| NCT06997029 | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | PHASE1 RECRUITING |
| NCT07001592 | Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors | PHASE1 RECRUITING |
| NCT07001748 | Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity | PHASE2|PHASE3 RECRUITING |
| NCT07023627 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | PHASE2 RECRUITING |
| NCT07024784 | A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies | PHASE2 RECRUITING |
| NCT07030283 | Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis | PHASE1 RECRUITING |
| NCT07030907 | A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer | PHASE1 RECRUITING |
| NCT07050771 | Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery | PHASE2 RECRUITING |
| NCT07059845 | A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer | PHASE2 RECRUITING |
| NCT07059884 | Distance-Based Exercise to Preserve Function and Prevent Disability | NA RECRUITING |
| NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | PHASE1|PHASE2 RECRUITING |
| NCT07078409 | Clinician Nudge to Referral of Adnexal Masses to Gynecologic Oncology | NA ENROLLING_BY_INVITATION |
| NCT07084168 | Multimedia Aid for Genetic Testing in Gynecologic Oncology | NA RECRUITING |
| NCT07090109 | PITCH - Impacting Hereditary Cancer Testing | NA NOT_YET_RECRUITING |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | PHASE1|PHASE2 RECRUITING |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT07144826 | Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy | EARLY_PHASE1 RECRUITING |
| NCT07151391 | The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue) | PHASE2 RECRUITING |
| NCT07158021 | Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial | PHASE2 RECRUITING |
| NCT07182149 | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | PHASE1 RECRUITING |
| NCT07186842 | A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 | PHASE1|PHASE2 RECRUITING |
| NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT07211659 | Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients | PHASE1 RECRUITING |
| NCT07213791 | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | PHASE1 RECRUITING |
| NCT07213804 | A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer | PHASE3 RECRUITING |
| NCT07214779 | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | PHASE3 RECRUITING |
| NCT07216105 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT07218809 | AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer | PHASE3 RECRUITING |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | PHASE2|PHASE3 RECRUITING |
| NCT07224464 | The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. | NA RECRUITING |
| NCT07225270 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy | PHASE3 RECRUITING |
| NCT07226427 | A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer | PHASE1 RECRUITING |
| NCT07229313 | A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors | PHASE1 RECRUITING |
| NCT07253662 | Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma | PHASE1 RECRUITING |
| NCT07265739 | Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer | PHASE2 NOT_YET_RECRUITING |
| NCT07278336 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer | PHASE1 RECRUITING |
| NCT07280312 | Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions | NA RECRUITING |
| NCT07282158 | Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians | NA RECRUITING |
| NCT07282834 | Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining) | PHASE2 RECRUITING |
| NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas | PHASE2 RECRUITING |
| NCT07287098 | A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer | PHASE2 RECRUITING |
| NCT07290309 | Survivors Uniting for Remote Guided Exercise | NA RECRUITING |
| NCT07303894 | A Study of Isoquercetin in People With Ovarian Cancer | PHASE2 RECRUITING |
| NCT07306559 | A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) | PHASE1 RECRUITING |
| NCT07310420 | A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer | PHASE1 RECRUITING |
| NCT07318558 | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) | PHASE3 RECRUITING |
| NCT07322094 | CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer | PHASE1|PHASE2 RECRUITING |
| NCT07360314 | Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT07381985 | Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment | NA ENROLLING_BY_INVITATION |
| NCT07389239 | A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. | PHASE1|PHASE2 RECRUITING |
| NCT07406087 | Navigation Intervention for Adolescent and Young Adult Cancer Survivors | NA RECRUITING |
| NCT07408258 | Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT07411599 | Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial") | PHASE1|PHASE2 RECRUITING |
| NCT07419490 | Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy | NA RECRUITING |
| NCT07424547 | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | PHASE1 RECRUITING |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | PHASE1|PHASE2 RECRUITING |
| NCT07444814 | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT07446855 | Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours | PHASE1|PHASE2 RECRUITING |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | PHASE2 RECRUITING |
| NCT07460752 | Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients | PHASE2 RECRUITING |
| NCT07470853 | A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | PHASE1 RECRUITING |
| NCT07475286 | Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis | PHASE2 RECRUITING |
| NCT07487168 | Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors | PHASE1 RECRUITING |
| NCT07488676 | A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT07489287 | GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer | PHASE1 RECRUITING |
| NCT07495124 | IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence | PHASE2 RECRUITING |
| NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | PHASE1 RECRUITING |
| NCT07504588 | Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy | PHASE2 RECRUITING |
| NCT07509008 | Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum | PHASE1|PHASE2 RECRUITING |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | PHASE1 RECRUITING |
| NCT07524322 | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT07542405 | A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families | NA NOT_YET_RECRUITING |
| NCT07546500 | A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression | PHASE3 RECRUITING |
| NCT07564141 | Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer | PHASE3 RECRUITING |
| NCT07591623 | OCRA Distress & Unmet Needs | NA NOT_YET_RECRUITING |
| NCT07593092 | Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT07596212 | BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder | PHASE1|PHASE2 NOT_YET_RECRUITING |
| NCT07634094 | Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer | PHASE2 NOT_YET_RECRUITING |
| NCT07636200 | The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer | NA RECRUITING |
| NCT07638410 | Prehabilitation in High-risk Oncologic Surgery | NA RECRUITING |
| NCT07653594 | TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) | NA NOT_YET_RECRUITING |
| NCT07658196 | TLR9 Immunotherapy for Peritoneal Carcinomatosis | PHASE1 RECRUITING |
| NCT07671937 | INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study | NA RECRUITING |
| NCT07690189 | Study of NTB-928 in R/R OC | PHASE1 RECRUITING |
| NCT07705035 | DBC-664 in Adult Patients With Solid Tumors | PHASE1 RECRUITING |
| NCT07718854 | Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer | PHASE2 RECRUITING |
| NCT07720180 | Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab | PHASE2 NOT_YET_RECRUITING |
| NCT07736937 | Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer | PHASE1|PHASE2 RECRUITING |
| NCT07741968 | A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer | NA RECRUITING |
| NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | PHASE1|PHASE2 RECRUITING |
| NCT07755436 | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. | PHASE1 RECRUITING |
| NCT07764744 | Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants | NA NOT_YET_RECRUITING |
| NCT07772869 | Uterine Lavage to Detect Ovarian Cancer Risk | NA RECRUITING |
| NCT07772882 | Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer | PHASE1 NOT_YET_RECRUITING |
| NCT07776691 | A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) | PHASE3 RECRUITING |
| NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | EARLY_PHASE1 NOT_YET_RECRUITING |
| NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | PHASE2 RECRUITING |
| NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | PHASE1|PHASE2 NOT_YET_RECRUITING |
| NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors | PHASE1 RECRUITING |
| NCT07815704 | Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin | PHASE2 NOT_YET_RECRUITING |
| NCT07816666 | Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer | PHASE3 RECRUITING |
| NCT07824960 | Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma | PHASE1|PHASE2 NOT_YET_RECRUITING |
| NCT07851025 | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer | PHASE3 RECRUITING |